NS Partners
REGN icon

NS Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

NS Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.61M Buy
+3,439
New +$2.6M 0.11% 101

Other funds holding REGN

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $187B AUM 13.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

NS Partners's REGN Position: Q3 2026 in Review

NS Partners opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2026: 3,439 shares worth $2.61M. The stake represents 0.11% of the portfolio and ranks #101 among its holdings.

1,212 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • NS Partners held 3,439 shares of Regeneron Pharmaceuticals worth $2.61M as of Q3 2026.
  • Regeneron Pharmaceuticals was a new NS Partners position in Q3 2026.
  • Regeneron Pharmaceuticals made up 0.11% of NS Partners's portfolio in Q3 2026, its #101 holding.
  • 1,212 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on NS Partners's 13F filing for Q3 2026, filed 10 Nov 2026.